Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120019/S043

cobas EGFR Mutation Test, v2.0

Roche · Decision date Mar 17, 2026

FDA DECISIONP120019/S043

What did the FDA decide?

FDA records P120019/S043 as a supplement to PMA P120019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 17, 2026.

FDA approval order statement

to revise QC methods for supplied materials
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Mar 17, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P120019/S043
Regulatory pathway
PMA supplement
Applicant
Roche
Product code
OWD
Decision code
OK30
Decision date
Mar 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Applicant
Roche
Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P120019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P120019 · Original PMA

    COBAS EGFR MUTATION TEST

  2. P120019/S042 · Related supplement

    cobas EGFR Mutation Test, v2.0

  3. P120019/S043 received

    Application receipt date recorded by FDA.

  4. P120019/S043 · FDA decision

    30-Day Notice

  5. P120019/S044 · Related supplement

    cobas EGFR Mutation Test, v2.0

  6. P120019/S045 · Related supplement

    Roche cobas EGFR Mutation Test, v2.0

Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120019

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA approvalMay 14, 2013FDA
RochePMA supplementDec 31, 2025FDA
RochePMA supplementOct 27, 2026FDA
RochePMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records